All episodes

Last week we heard the diabetologist's perspective on cardiovascular outcomes. In this weeks episode, EASD TV continues its deep dive into major clinical trials with the cardiologist’s perspective. Cardiologist Dr. Matthew Cavender (University of North Carolina) joins Vivienne Parry to unpack the SOUL trial, a major cardiovascular outcomes study evaluating oral semaglutide in people with type 2 diabetes.

The trial followed more than 8,000 high-risk participants and demonstrated a 14% reduction in major cardiovascular events, including cardiovascular death, myocardial infarction and stroke. Dr Cavender explains why having an effective oral GLP-1 receptor agonist is an important development for both diabetes...

At the EASD 2024 Annual Meeting, the SOUL trial attracted significant attention as the first study to show cardiovascular risk reduction using an oral GLP-1 receptor agonist. In this episode, Dr Rodica Busui (Oregon Health & Science University-OHSU, Oregon, USA) explains the trial’s major outcomes, including a 14% reduction in major adverse cardiovascular events -matching results previously observed with injectable GLP-1 formulations.

The discussion highlights the potential impact of an oral agent on clinical practice, including improved accessibility, suitability for older adults, and earlier use in the treatment pathway. Dr Busui also reviews new data on heart failure phenotypes, particularly...

In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) join host Vivienne Parry to discuss the groundbreaking ATTAIN trial, presented at the EASD 2025 Annual Meeting in Vienna.

The trial tested Orforglipron, the first oral small molecule GLP-1 receptor agonist, showing promising results in weight reduction and cardiometabolic improvements among people living with overweight or obesity.

Beyond the data, the discussion explores what makes Orforglipron different, from its potential to expand access and affordability, to its implications for type 2 diabetes prevention. With obesity...

What does the future hold for beta cell biology and diabetes treatment? Join Prof. Raphaël Scharfmann (INSERM), recipient of the 2025 Albert Renold Prize, as he explores how developmental biology is unlocking new ways to generate functional beta cells - an important step toward curing diabetes.
In this inspiring interview from the EASD 2025 Annual Meeting in Vienna, Prof. Scharfmann discusses the progress in stem cell-derived beta cell generation, the collaboration driving translational research, and the next big challenge, counting beta cells in the living human pancreas.
Discover how decades of research are shaping the next frontier in diabetes science...

In this episode, Vivienne Parry introduces the EASD Rising Stars of 2025, four early-career researchers whose work spans exercise physiology, precision diabetes medicine, childhood obesity, and metabolic biology.

Dr Sindre Lee-Ødegård (Norway) explores exercise as medicine for highrisk groups; Dr Martin Schön (Slovakia/Germany) works on precision diabetes diagnosis and lifestyle interventions; Dr Cadenas-Sánchez (Spain) investigates childhood obesity and brain health; and Dr Jens Lund (Denmark) uncovers how metabolites like lactate act as powerful signalling molecules.

From exercise as medicine to precision diabetes care, childhood obesity, and molecular metabolism, these young scientists are redefining how we understand, prevent, and treat diabetes.Together,...

In this episode, Dr. Viswanathan Mohan, recipient of the inaugural EASD Global Impact Prize, reflects on his remarkable 50-year career transforming diabetes care in India and worldwide. From pioneering diabetes as a medical speciality and training over 29,000 educators, to leading translational research and nationwide screening initiatives, Dr. Mohan’s work has set new benchmarks in global health impact.

He discusses the evolving causes of India’s diabetes epidemic, from genetics and high-carbohydrate diets to pollution and urbanisation, and the policies needed to address them. Dr. Mohan also explores how innovation, affordability, and access to technologies like continuous glucose monitoring (CGM) can...

In this episode, EASD TV host Vivienne Parry sits with Prof. Mikael Rydén (Karolinska Institute), recipient of the 40th Camillo Golgi Prize, about his groundbreaking research on adipose tissue.

Prof. Rydén shares insights into how different fat cell subtypes influence disease progression, particularly in diabetes and obesity. His work highlights the potential of precision medicine in tailoring treatments based on the composition of adipose tissue, shifting the focus from generalised treatments to more personalised approaches.

Join us for a deep dive into how Prof. Rydén’s research is revolutionising diabetes care and what it means for the future of metabolic health.

In this episode, Dr Teresa Mezza, recipient of the 2025 EASD Minkowski Prize, takes listeners inside her pioneering research on the early mechanisms of type 2 diabetes. As both a clinician and researcher at the Fondazione Policlinico Universitario A. Gemelli in Rome, Dr Mezza studies patients before and after partial pancreatectomy, offering a unique perspective on beta cell adaptation, function, and decline.

Her work is revealing early biomarkers that could identify individuals at risk of diabetes - even before hyperglycaemia develops - paving the way for earlier intervention and prevention. Dr Mezza also discusses the importance of translational research, the...

In this episode, EASD host, Vivienne Parry sits down with 2025 EASD Claude Bernard Prize recipient, Prof. Andrew Hattersley, to reflect on his career which has transformed diabetes research and care worldwide. From the discovery of key genetic mutations in maturity onset diabetes of the young (MODY) and neonatal diabetes to establishing a global genetic testing programme that has helped patients in more than 100 countries, Prof. Hattersley has shaped our understanding of diabetes.

Tune in to hear reflections on his early breakthroughs, the team collaborations that made them possible, and the far-reaching clinical impact of precision medicine for children...

In this episode, we meet Prof Gerald Shulman, recipient of this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, whose pioneering research has reshaped our understanding of insulin resistance and its role in type 2 diabetes and beyond.

Prof. Shulman shares insights from over four decades of research into how ectopic lipid accumulation disrupts insulin signalling, leading to diabetes, fatty liver disease, cardiovascular complications, cancers, and Alzheimer’s disease. He explains how his discoveries - from the role of diacylglycerols to innovative mitochondrial-targeted therapies now in clinical trials - could mark a paradigm shift in the treatment of insulin resistance.

Join...